Tweet
<img alt="" height="1" width="1" />
Novo Nordisk obesity drug results underwhelm investors
Reuters
COPENHAGEN | Mon Mar 18, 2013 9:24am EDT. COPENHAGEN (Reuters) - Overweight and obese diabetes patients given high doses of Novo Nordisk's drug liraglutide achieved 6 percent weight loss in a clinical trial, only slightly above the loss seen in ...
Novo Drops as JPMorgan Says Rivals Gain Ground: Copenhagen MoverBloomberg
New study shows Novo Nordisk's Victoza achieves 6% weight loss in type 2 ...The Pharma Letter
Novo Nordisk Releases its Annual Social, Environmental and Financial ResultsJustmeans
Mideast Time -Marketwire (press release) -PharmaLive (press release) (subscription)
all 9 news articles »
More...